Detalhe da pesquisa
1.
Chimeric antigen receptor T-cell therapy in acute myeloid leukemia.
Curr Opin Hematol
; 29(2): 74-83, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35013048
2.
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.
Blood
; 137(22): 3145-3148, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624009
3.
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
Br J Haematol
; 155(5): 599-606, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21981697
4.
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Clin Lymphoma Myeloma Leuk
; 10(2): 138-43, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20371448
5.
Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
Leuk Lymphoma
; 54(4): 874-7, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22971215